Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2013

GSK Pays Isis $5M for Antisense Drug Advancement

  • Isis Pharmaceuticals has earned a $5 million milestone payment from GlaxoSmithKline (GSK) related to the designation of ISIS-GSK4Rx, an antisense drug designed to treat an undisclosed ocular disease, as a development candidate.

    As a part of the alliance, Isis is eligible to earn additional prelicensing milestone payments from GSK as ISIS-GSK4Rx advances. The company will develop ISIS-GSK4Rx to Phase II proof-of-concept, at which time GSK has the option to exclusively license it. Isis is also eligible to receive double-digit royalties on sales of the candidate.

    Isis and GSK's antisense collaboration began in March 2010 when GSK paid Isis $35 million upfront to discover new antisense drugs against serious rare disorders including infectious diseases and specific conditions causing blindness. Last month, GSK added ISIS-GSK3Rx to the program, earning Isis $7 million in milestone payments.

    Collaboration between the two firms has resulted in three antisense drugs in Isis’ pipeline. In July, the company won a $2 million milestone payment from GSK for the advancement of an ongoing Phase II/III study of ISIS-TTRRx, an antisense drug being developed for the rare genetic disease transthyretin amyloidosis. In the deal, Isis received $20 million in up-front and milestone payments before the dosing of the first patient in the study, including a $7.5 million payment it earned in February upon initiation of the trial.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »